New Oral Pill Shows Promise in Reducing Sleep Apnea Events by 44%

A once-nightly oral medication, AD109, significantly improved obstructive sleep apnea (OSA) in a large Phase 3 clinical trial. The drug, designed to target neuromuscular problems contributing to airway collapse during sleep, cut breathing interruptions by approximately 44% and improved oxygen levels and disease severity. Presented at the 2026 ATS International Conference, these results offer a potential new treatment option for individuals unable to tolerate Continuous Positive Airway Pressure (CPAP) therapy.